The Latest Breaking News from BMY

Amid rising global medical needs, the pharmaceutical industry is expected to witness robust growth in the coming years. Moreover, healthcare is considered relatively resilient amid market downturns. So, given the economic uncertainties, investors could consider buying quality pharmaceutical stocks such as Pfizer (PFE), Novartis (NVS), and Bristol-Myers Squibb (BMY) this…

While the moderate inflation rate for November has boosted investor sentiment and may have paved the way for lower interest rate hikes from this month, Fed’s recent comments suggest that the target interest rate may be a bit further ahead. Hence shares of fundamentally strong businesses with robust demand, such…

This top health stock stands out with its proven year-over-year earnings growth record, increased earnings estimates and hefty 2.7% dividend.

Despite economic uncertainties, leading pharma company Bristol-Myers Squibb (BMY) beat street estimates in the fiscal third quarter with solid financials. However, given the current market turmoil, is it too late to get on the upward move in this stock? Continue reading to find out.

The Fed Chairman recently indicated a slower pace of rate increases. However, many analysts still believe the economy will face a mild recession next year. Therefore, it could be wise to invest in quality stocks with solid growth prospects, such as AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Lifeway Foods (LWAY).…

Consumer confidence dropped month-over-month in November. However, it remains well above the mark, indicating a healthy economy. We think investors’ quality stocks, UnitedHealth Group (UNH) and Bristol-Myers Squibb (BMY), which have solid dividend-paying records, could help navigate the uncertainties. However, fundamentally weak Peloton Interactive (PTON) and Mullen Automotive (MULN) might…

The Fed is likely to slow down its aggressive monetary policy as analysts believe the economy is finally losing momentum and inflation should decline in the next year. Therefore, investors should consider adding fundamentally sound stocks Bristol-Myers (BMY) and ARC Document (ARC) to their portfolios to ensure a stable passive…

Although the stock market has seen a decline in inflation for October, it is far from the Fed’s target, and rate hikes might continue. However, the anticipation of a strong stock market rebound in 2023 is rising. So, we think it could be wise to load up on fundamentally sound…

Biopharmaceutical major Bristol-Myers Squibb Company (BMY) beat the consensus earnings and revenue estimates in the third quarter. Given its strong product pipeline, strategic acquisitions, discounted valuation, high profitability, strong financials, and attractive dividends, investors could buy the stock now. Read more….